Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mark Oliver who wrote (1056)	2/4/2000 11:30:00 AM
From: caly	Read Replies (1) \| Respond to of 1605

Friday February 4, 10:44 am Eastern Time Company Press Release The American College of Cardiology Reviews External Counterpulsation WESTBURY, N.Y.--(BUSINESS WIRE)--Feb. 4, 2000--Vasomedical, Inc. (Nasdaq:VASO - news) announced today that the American College of Cardiology (ACC), a highly respected professional association for cardiologists, recently reviewed external counterpulsation therapy in response to a request from the Health Care Financing Administration (HCFA), the federal agency that administers Medicare. Comments on the ACC review of external counterpulsation were published in the January 2000 issue of Cardiology, the College's official newsletter. After examining the multi-center controlled MUST-EECP study and other recent scientific publications on external counterpulsation treatment, the ACC submitted a formal opinion on this therapy. In a letter to HCFA, the ACC recommended that ''physicians consider external counterpulsation as a therapeutic option for patients with drug-refractory angina who are not candidates for other forms of therapy, specifically coronary artery interventions (PTCA with or without stenting) and surgical revascularization (CABG).'' D. Michael Deignan, recently appointed CEO of Vasomedical, commented, ''We are gratified that the American College of Cardiology has reviewed the current literature on EECP therapy and essentially agreed with the HCFA national coverage decision which became effective July 1, 1999 and was reaffirmed in November. We were also pleased to note that EECP therapy was preferred over TMR in the same group of patients in several recent editorials and articles in such publications as Clinical Cardiology, Healthnews, an American Heart Association newsletter, and The New England Journal of Medicine.'' Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting external counterpulsation systems based on the company's proprietary technology. EECP® is a registered trademark for Vasomedical's enhanced external counterpulsation system. This system is now in use at major medical centers, including the Mayo Clinic, the Ochsner Foundation Hospital and the Miami Heart Institute, as well as medical centers affiliated with Columbia University, the University of Pittsburgh, the University of California San Diego, the University of California San Francisco, and the University of Virginia. The company provides hospitals, clinics and private practices EECP® equipment, treatment guidance and a staff training and maintenance program to ensure optimal patient outcomes. Except for historical information contained in this news release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as ''anticipate,'' ''believe,'' ''estimate'' and ''intend'' and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments. -------------------------------------------------------------------------------- Contact: Vasomedical, Inc. Anthony Peacock, 516/997-4600 Ext. 120 eecp.com/news or MediaMedica, Inc. Jeanette Hutter, 215/402-9175